Cynvenio is a cancer diagnostics company focused on transforming cancer treatment and management through the molecular analysis of cancer biomarkers in blood.
The company’s genomic blood testing methodology offers advantages for doctors and patients where traditional tissue pathology may fall short. These scenarios include Cynvenio’s ability to open a new treatment window for metastatic patients who are unresponsive to second or third line therapy, possibly because of the onset of resistance mutations; or where it is desirable to serially test patients to monitor their response to therapy without subjecting them to frequent radiology procedures.